Diatrizoic Acid

CHEMBL1201220 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
613.9 g/mol
LogP
1.8
Phase
4

An iodinated contrast medium used in various radiological imaging procedures to enhance the visibility of blood vessels and body cavities on X-rays and CT scans. It works because its iodine atoms strongly absorb X-ray radiation, creating bright white images of the structures it fills. Allergic reactions ranging from mild flushing to severe anaphylaxis are possible.

น้ำหนักโมเลกุล

613.9100 g/mol

LogP

1.80

TPSA

95.50 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I

InChI

InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)

Molecular Formula

C11H9I3N2O4

HBD / HBA

3 / 4

พันธะที่หมุนได้

3

อะตอมหนัก

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An iodinated contrast medium used in various radiological imaging procedures to enhance the visibility of blood vessels and body cavities on X-rays and CT scans. It works because its iodine atoms strongly absorb X-ray radiation, creating bright white images of the structures it fills. Allergic reactions ranging from mild flushing to severe anaphylaxis are possible.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Diatrizoic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201220. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2140. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.